Why the study?
Despite an expanding antiplatelet arsenal, thromboembolic cardiovascular diseases remain the leading cause of mortality worldwide, driving an urgent demand for more effective and safer novel therapeutic alternatives.
This review summarizes the historical evolution and structural patterns of P2Y12 receptor antagonists to aid in the design of new antiplatelet agents.
May support novel P2Y12 antagonists; leaves open clinical efficacy and safety in thromboembolic disease.
The therapeutic arsenal of antiplatelet drugs available for clinical use has expanded significantly in recent decades.However, despite this, cardiovascular diseases associated with thromboembolic disorders still represent the main cause of mortality in Brazil and around the world.This panorama indicates the urgent demand for the development of more effective and safer novel therapeutic alternatives.In this context, P2Y 12 receptor antagonists stand out, once these drugs represent the first-choice treatment in the management of coronary artery disease and other cardiovascular disorders.This paper provides an historical overview of the evolution of these antagonists, starting from the first agents, following with the description of the development of P2Y 12 antagonists currently in clinical use, and finally reporting the most recent discovery of new structural patterns for modulation of this key therapeutic target.In addition to reviewing and updating the topic, this work provides a useful collection of structural information for further design of new chemical entities as P2Y 12 receptor antagonists.
No takes yet. Share an insight, caveat, or question.
Silva et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: